

June 19, 2019

IMAP advises pharma quality control company Lixis on cross-border sale to SEA Vision

IMAP is pleased to announce the sale of pharmaceutical quality control company Lixis, to SEA Vision, a global leader in pharmaceutical inspection systems. Terms of the transaction were not disclosed.

SEA Vision is an Italian company specializing in vision and track-and-trace systems for the pharmaceutical industry, with a consolidated turnover of €60 million. Lixis is an Argentinian company with over 17 years of experience in pharmaceutical vision, control and track-and-trace systems.

The operational synergies between the companies will enable SEA Vision to become the leading group providing both software and hardware in its target market in Latin America, with a local workforce of 70 professionals. Lixis has already been collaborating with SEA Vision in the Brazilian market through the São Paulo-based subsidiary SEA Vision Latin America (SVLA).

IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.

INDUSTRIALS



SEA VISION
Pharma industry quality control
systems and solutions
ITALY

Acquired 100% of Business Operations



Quality control for pharma industry packaging
ARGENTINA



ADVISED ON SALE OF COMPANY



Pablo Teubal
Partner
IMAP Argentina
pablo.teubal@imap.com



Pedro Querio
Partner
IMAP Argentina
pedro.querio@imap.com

For more information on IMAP transactions visit www.imap.com



IMAP is an International Mergers and Acquisitions Partnership, with 450 M&A professionals and a presence in 40 countries. IMAP has closed over 2,100 transactions valued at \$90 billion in the last 10 years and is consistently ranked among the world's top ten M&A advisors for mid-market transactions (Thomson Reuters). IMAP advises primarily mid-sized companies and their shareholders on sales and acquisitions globally, providing clients with entrepreneurial, unbiased advice and successfully helping them achieve their objectives.